Synopsis: Propanc Biopharma secured up to $100 million from Hexstone Capital to build a crypto treasury funding its cancer therapy PRP. The plan aims to accelerate trials but drew mixed investor reactions.
Propanc Biopharma, an Australia-based biotech firm, has secured up to $100 million from Hexstone Capital to create a crypto treasury supporting its cancer treatment development. This move aims to strengthen Propanc’s finances and accelerate clinical trials for its novel therapy by late 2026. However, the market’s reaction was mixed, reflecting skepticism about combining biotech with crypto strategies.
Propanc’s Crypto Treasury Initiative
Propanc Biopharma has entered a transformative phase by raising $100 million from Hexstone Capital, a crypto-focused family office. The initial $1 million investment has already been received, with an option to draw the remaining $99 million over the next 12 months through convertible preferred stock. This funding will build a digital asset treasury and push forward Propanc’s lead cancer therapy, PRP, which targets metastatic solid tumors and aims to enter human trials by mid-2026.
CEO James Nathanielsz emphasized that building a crypto treasury will enhance the company’s balance sheet, allowing faster clinical development while diversifying assets. He highlighted that PRP’s proenzyme therapy could treat not only cancer but other chronic diseases as well. Although the specific cryptocurrencies for the treasury were undisclosed, Hexstone’s investments include Bitcoin, Ethereum, Solana, and other tokens, suggesting a diversified crypto portfolio.
Unconventional Strategy
Propanc’s strategy to fund cancer R&D via crypto places it among a growing group of biotech firms adopting similar tactics to attract new investors. Unlike traditional equity or debt financing, the crypto treasury plan offers potential liquidity and capital efficiency benefits. However, investors reacted cautiously Propanc’s Nasdaq shares dropped about 10.5% on the announcement day.
This skepticism is understandable, as other companies holding Bitcoin treasuries have faced recent valuation declines. For example, Strategy, the largest corporate Bitcoin holder, experienced a market value drop of more than 43% since July. Similar downturns led some firms to sell crypto assets to cover debts, raising questions about the sustainability of crypto treasury models in biotech.
The Cancer Treatment at Stake
Propanc is advancing PRP, a unique proenzyme-based therapy designed to selectively attack metastatic cancer cells while preserving healthy tissue. This approach contrasts with harsh treatments like chemotherapy. Preclinical trials showed promising tumor reduction and potential use for other inflammatory diseases. Propanc plans to start Phase I human efficacy trials by late 2026, supported partly by this new crypto funding.
The cancer therapy market exceeds $200 billion globally. PRP’s novel mechanism could offer an important alternative to existing immunotherapies. The fresh capital will also support manufacturing scale-up, intellectual property growth, and regulatory preparations, positioning Propanc for potential partnerships with major pharmaceutical companies.
Crypto Biotech: Hit or Miss?
Propanc’s move to combine biotech innovation with crypto financing is cutting-edge but risky. The company hopes that leveraging digital assets can boost investor interest and secure operational funding without immediate equity dilution. However, crypto market volatility and regulatory uncertainties pose ongoing risks.
Still, this fusion of biotechnology and blockchain finance could inspire others in the oncology space, especially as venture capital tightens. Success depends on PRP’s clinical progress and crypto asset performance. For now, watching Propanc’s development and market reception will reveal if such hybrid strategies can sustain growth and deliver breakthroughs or remain speculative gambles.
Written By Fazal Ul Vahab C H
